Article Information
History
- April 1, 2021.
Article Versions
- You are currently viewing Version 1 of this article (April 1, 2021 - 13:55).
- Version 2 (July 5, 2021 - 14:55).
- View Version 3, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Emily C. Gale1,
- Abigail E. Powell1,2,
- Gillie A. Roth3,
- Ben S. Ou3,
- Emily L. Meany3,
- Abigail K. Grosskopf5,
- Julia Adamska7,8,
- Vittoria C. T. M. Picece4,6,
- Andrea I. d’Aquino4,
- Bali Pulendran2,7,8,9,
- Peter S. Kim1,2,10 and
- Eric A. Appel2,3,4,8,11,*
- 1Department of Biochemistry, Stanford University School of Medicine, Stanford, CA 94305, USA
- 2Stanford ChEM-H, Stanford University, Stanford, CA 94305, USA
- 3Department of Bioengineering, Stanford University, Stanford, CA 94305, USA
- 4Department of Materials Science & Engineering, Stanford University, Stanford, CA 94305, USA
- 5Department of Chemical Engineering, Stanford University, Stanford, CA 94305, USA
- 6Department of Chemistry and Applied Biosciences, ETH Zurich, Zurich 8093, Switzerland
- 7Department of Microbiology & Immunology, Stanford University School of Medicine, Stanford, CA 94305, USA
- 8Institute for Immunity, Transplantation, & Infection, Stanford University School of Medicine, Stanford, CA 94305, USA
- 9Department of Pathology, Stanford University School of Medicine. Stanford, CA 94306, USA
- 10Chan Zuckerberg Biohub, San Francisco, CA 94158, USA
- 11Department of Pediatrics - Endocrinology, Stanford University School of Medicine, Stanford, CA 94305, USA
- ↵*corresponding author: eappel{at}stanford.edu
Posted April 01, 2021.
Hydrogel-based slow release of a receptor-binding domain subunit vaccine elicits neutralizing antibody responses against SARS-CoV-2
